Elicio Therapeutics Inc.

Can-Fite BioPharma, SeaStar Medical, and Elicio Therapeutics were among the top biotech gainers on Wednesday. Can-Fite soared over 55% after its Phase 2a pancreatic cancer study with Namodenoson met its primary safety endpoint and showed durable overall survival, prompting plans for a Phase 2b combination trial. SeaStar Medical jumped more than 30% as net revenue for its flagship QUELIMMUNE pediatric therapy rose to approximately $0.5 million in the first quarter of 2026 from $0.3 million a year earlier, with full-year 2026 product revenue expected to reach about $2 million. Elicio Therapeutics climbed over 31% following its addition to the Russell 2000 and Russell 3000 Indexes and the refinement of its Phase 3 development strategy for ELI-002, despite the Phase 2 AMPLIFY-7P trial missing its primary endpoint. Regentis Biomaterials gained more than 29% as it prepares to begin European surgeon training for its CE Mark-approved knee cartilage implant GelrinC. TransCode Therapeutics rose over 20% for a second straight day, with a Phase 2a trial of its metastatic cancer therapy TTX-MC138 underway and preliminary results expected in the fourth quarter of 2026. Outset Medical advanced over 18% after reporting first-quarter 2026 revenue of $27.9 million and projecting full-year revenue between $125 million and $130 million.

uniQure led a group of biotech gainers on Wednesday after the FDA softened its stance on the company’s investigational gene therapy AMT-130 for Huntington’s disease. The agency now considers the 3-year analysis from the Phase I/II study acceptable as the primary basis for a Biologics License Application for accelerated approval, reversing its earlier recommendation for a prospective, randomized, double-blind, sham-surgery-controlled study. uniQure intends to submit the BLA in the third quarter of 2026, and its shares closed at $48.16, up 78.44%. Other notable movers included Elicio Therapeutics, which rose 70.65% after reporting that three advanced pancreatic cancer patients in its Phase 2 AMPLIFY-7P study achieved complete responses following treatment with its vaccine ELI-002 7P and subsequent checkpoint inhibitor therapy. Lunai Bioworks gained 40.06% after its CEO outlined developments including a first revenue-generating U.S. government defense contract and the formation of the Pathfinder Consortium. ClearPoint Neuro climbed 26.01% on spillover optimism related to uniQure’s AMT-130, which is administered using ClearPoint’s navigation system. Polyrizon added 15.55% after the publication of a U.S. patent application for its nasal drug delivery technology, and Faeth Therapeutics rose 14.59% as it anticipates topline data from a Phase 2 trial of its lead candidate PIKTOR in advanced endometrial cancer in the second half of 2026.